Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril

• Published in: European journal of clinical pharmacology Vol. 71; no. 8; pp. 949 - 957
• Main Authors: Oliveira-Paula, G. H., Lacchini, R., Fontana, V., Silva, P. S., Biagi, C., Tanus-Santos, Jose E.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.08.2015; Springer Nature B.V
• Subjects: Adult; Antihypertensive Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; Blood Pressure - drug effects; Drug therapy; Enalapril - therapeutic use; Female; Genes; Genotype; Heart Rate - drug effects; Humans; Hypertension; Hypertension - drug therapy; Hypertension - genetics; Hypertension - physiopathology; Male; Middle Aged; Pharmacogenetics; Pharmacology/Toxicology; Polymorphism; Polymorphism, Genetic; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - genetics; Haplotypes; Hypertension; Enalapril; Polymorphisms

Purpose Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that affects blood pressure by promoting vasodilation mediated by nitric oxide. Angiotensin-converting enzyme inhibitors (ACEi) up-regulate the VEGF expression; thus, genetic polymorphisms in the VEGFA gene could affect...